Quantcast

Latest Spasmodic torticollis Stories

2010-04-13 07:11:00

GREENSBORO, N.C., April 13 /PRNewswire/ -- Merz Pharmaceuticals announces that results from several new studies examining Xeomin® (incobotulinumtoxinA), a botulinum neurotoxin type A (free from complexing proteins), also referred to as NT 201, will be presented today at the 62nd American Academy of Neurology (AAN) annual meeting in Toronto, Canada. Results of studies exploring the safety and efficacy of Xeomin® in the treatment of focal dystonias...

2009-06-19 09:50:00

WASHINGTON, June 19 /PRNewswire/ -- The Center for Laser Surgery, Washington, DC has announced the availability of Dysport, abobotulinum toxin-A. Dysport, recently FDA approved, is the first cosmetic neurotoxin available alongside the widely used BOTOX(R) Cosmetic (botulinum toxin-A). The Center for Laser Surgery was principal investigator of the FDA Stage III Clinical Trials for Dysport. As Washington, DC, Maryland and Virginia's largest and most experienced Botox practice, the center was...

2009-06-09 06:00:00

-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA)...

2009-06-08 06:00:00

--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the Movement Disorder Society (MDS) 13th annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for...

992a46b98d5da0cb0fcaecb09350e7001
2009-04-30 15:40:00

U.S. regulators warned consumers and doctors on Thursday about potentially deadly complications that can arise from off-label use of Allergan Inc.'s Botox and similar drugs. The U.S. Food and Drug Administration (FDA) said the wrinkle-smoother Botox and two other injections carry risks of rare botulism symptoms, especially when given to children to treat muscle spasms. Botulinum toxin can paralyze or relax muscles.  Although the drug is perhaps best known for its use as a wrinkle...

2009-04-28 11:07:00

SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at the American Academy of Neurology's (AAN) 61st annual meeting in Seattle. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the...

2009-04-15 08:00:00

New Patient Video Vignettes and Mechanism of Action 3-D Video Illustrate the Versatility and Application of BOTOX(R) Across Several Approved Indications IRVINE, Calif., April 15 /PRNewswire-FirstCall/ -- As part of the nearly 20-year milestone since the first approved indications by the U.S. Food and Drug Administration (FDA) for BOTOX(R) (Botulinum Toxin Type A), Allergan, Inc. (NYSE: AGN), the maker of BOTOX(R) and BOTOX(R) Cosmetic, conducted a Web-based media briefing that provided an...

2008-12-26 13:38:00

New Prescription Product Increases Length, Thickness and Darkness of Eyelashes IRVINE, Calif., Dec. 26 /PRNewswire-FirstCall/ -- Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE(TM) is the first and only science-based treatment approved by...

2008-09-30 03:00:30

Regulatory News: Ipsen (Paris:IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport(R) (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing. The FDA has not requested...

2008-08-07 09:00:14

BOTOX(R) is an important medicine that over the last 15 years of clinical use has helped millions of patients with serious medical conditions worldwide. Pharmaceutical manufacturers using Clostridium botulinum toxin (BOTOX(R)) in drugs are required by the Food and Drug Administration (FDA) in the United States and by other worldwide health regulatory agencies to protect patients and consumers by assuring product safety and efficacy through animal testing and other methods. In a recent...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related